Devonian Health GroupDVHGF 49 FCF Margin % is -1,093.22% as of Jan. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 954 Biotechnology companies, Devonian Health Group ranks worse than 51.78% on this metric.
The historical rank and industry rank for Devonian Health Group's FCF Margin % or its related term are showing as below:
DVHGF'
s FCF Margin % Range Over the Past 10 Years
Min: -185.76 Med: -82.96 Max: 29.2
Current: -96.3
During the past 12 years, the highest FCF Margin % of Devonian Health Group was 29.20%. The lowest was -185.76%. And the median was -82.96%.
DVHGF's FCF Margin % is ranked worse than 51.78% of 954
companies
in the Biotechnology industry
Industry Median: -84.535
vs DVHGF: -96.30
Devonian Health Group FCF Margin % Related Terms
Devonian Health Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Devonian Health Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DVHGF) has a FCF Margin % of -1,093.22% as of Jan. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #494 out of 954 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Devonian Health Group's FCF Margin % too high?
Devonian Health Group's current FCF Margin % is -1,093.22%. Based on the distribution chart, Devonian Health Group ranks #494 out of 954 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #494 out of 954 companies for FCF Margin %. This places Devonian Health Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current FCF Margin % is -1,093.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current FCF Margin % is -1,093.22%. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current FCF Margin % is -1,093.22% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
FCF Margin %: -1,093.22%
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
